Is virpax pharmaceuticals efficiently growing its dividend?
Virpax Pharmaceuticals does not have a long track record of dividend growth. In the past three months, Virpax Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $115,537.00 in company stock and sold $0.00 in company stock.
How much is vrpx stock worth?
One share of VRPX stock can currently be purchased for approximately $2.81. How much money does Virpax Pharmaceuticals make? Virpax Pharmaceuticals has a market capitalization of $32.92 million.
What does virpax stand for?
BERWYN, Pa., January 04, 2022--Virpax® Pharmaceuticals, Inc. ("Virpax"), a company specializing in product candidates for pain management, CNS disorders and anti-viral indications, today announced that it will be presenting virtually at the upcoming H. C. Wainwright event from Monday, January 10th through Thursday, January 13th starting at 7:00 a.
What does vrpx stand for?
WEST CHESTER, PA / ACCESSWIRE / February 19, 2021 / Virpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its common stock at a public offering price of $10.
Is Virpax Pharmaceuticals a buy?
Virpax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Will VRPX stock go up?
No changes to the price of Virpax Pharmaceuticals, Inc. stock on the last trading day (Thursday, 21st Jul 2022). During the day the stock fluctuated 3.18% from a day low at $1.57 to a day high of $1.62. The price has been going up and down for this period, and there has been a -9.14% loss for the last 2 weeks.
Is VRPX stock a buy?
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Virpax Pharmaceuticals (VRPX – Research Report), with a price target of $4.00.
Should I buy or sell Virpax Pharmaceuticals stock right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Virpax Pharmaceuticals in the last year. There are currently 2 buy ratings...
What is Virpax Pharmaceuticals' stock price forecast for 2022?
2 brokers have issued twelve-month price objectives for Virpax Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they...
How has Virpax Pharmaceuticals' stock price performed in 2022?
Virpax Pharmaceuticals' stock was trading at $3.43 on January 1st, 2022. Since then, VRPX stock has decreased by 55.4% and is now trading at $1.53....
Are investors shorting Virpax Pharmaceuticals?
Virpax Pharmaceuticals saw a drop in short interest in May. As of May 31st, there was short interest totaling 87,600 shares, a drop of 35.0% from t...
When is Virpax Pharmaceuticals' next earnings date?
Virpax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast fo...
Who are Virpax Pharmaceuticals' key executives?
Virpax Pharmaceuticals' management team includes the following people: Mr. Anthony P. Mack M.B.A. , Chairman & CEO (Age 60, Pay $600k) ( LinkedI...
Who are some of Virpax Pharmaceuticals' key competitors?
Some companies that are related to Virpax Pharmaceuticals include IMV (IMV) , NightHawk Biosciences (NHWK) , Merrimack Pharmaceuticals (MACK) ,...
When did Virpax Pharmaceuticals IPO?
(VRPX) raised $15 million in an IPO on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. Th...
What is Virpax Pharmaceuticals' stock symbol?
Virpax Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRPX."
About Virpax Pharmaceuticals
Virpax Pharmaceuticals (NASDAQ:VRPX) Frequently Asked Questions
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management.
News & Analysis: Virpax Pharmaceuticals, Inc
Virpax Pharmaceuticals saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 60,100 shares, a decline of 70.4% from the December 31st total of 203,000 shares. Based on an average daily trading volume, of 923,000 shares, the short-interest ratio is currently 0.1 days.
Environmental, Social, and Governance Rating
There is no available coverage of Virpax Pharmaceuticals, Inc. at this time.
Premium Research for VRPX
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
